Achieve Life Sciences (ACHV) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 118.1% versus a loss of 83.4%. Achieve Life Sciences is the larger company by market cap ($742.3 million vs $201.5 million), about 3.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | NNNN |
|---|---|---|
| Share price | $7.20 | $4.59 |
| Market cap | $742.34M | $201.46M |
| 1-day change | -0.55% | -6.33% |
| YTD return | +45.67% | -83.70% |
| 1-year return | +118.07% | -83.37% |
| 5-year return | -10.06% | — |
| P/E ratio (TTM) | — | 30.60 |
| EPS (TTM) | $-1.69 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $44.73 |
| 52-week low | $2.62 | $4.56 |
| Distance from 52-week high | -16.67% | -89.74% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +96.53% | — |
| Average volume | 1.44M | 147.21K |
| Shares outstanding | 103.10M | 43.89M |
| Employees | 28 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 3.7 times larger than Anbio Biotechnology by market value ($742.34M vs $201.46M).
- ACHV has outperformed NNNN by 201.4 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
ACHV vs NNNN FAQ
Which is bigger, Achieve Life Sciences or Anbio Biotechnology?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $742.34M compared with $201.46M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, ACHV or NNNN?
ACHV returned +118.07% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.